Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apyx Medical (APYX) Receivables (2016 - 2026)

Apyx Medical filings provide 16 years of Receivables readings, the most recent being $17.1 million for Q4 2025.

  • On a quarterly basis, Receivables rose 7.53% to $17.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $17.1 million, a 7.53% increase, with the full-year FY2025 number at $17.1 million, up 7.53% from a year prior.
  • Receivables hit $17.1 million in Q4 2025 for Apyx Medical, up from $13.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $17.1 million in Q4 2025 to a low of $8.8 million in Q1 2021.
  • Median Receivables over the past 5 years was $12.4 million (2022), compared with a mean of $12.3 million.
  • Biggest five-year swings in Receivables: surged 68.45% in 2021 and later dropped 26.01% in 2022.
  • Apyx Medical's Receivables stood at $13.5 million in 2021, then fell by 17.26% to $11.2 million in 2022, then rose by 29.65% to $14.5 million in 2023, then rose by 9.34% to $15.9 million in 2024, then grew by 7.53% to $17.1 million in 2025.
  • The last three reported values for Receivables were $17.1 million (Q4 2025), $13.0 million (Q3 2025), and $11.2 million (Q2 2025) per Business Quant data.